FY2029 Earnings Forecast for SCPH Issued By HC Wainwright

scPharmaceuticals Inc. (NASDAQ:SCPH) – Stock analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of scPharmaceuticals in a research report issued on Monday, March 3rd. HC Wainwright analyst D. Tsao forecasts that the company will post earnings per share of $0.70 for the year. HC Wainwright currently has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for scPharmaceuticals’ current full-year earnings is ($1.53) per share.

Separately, Craig Hallum decreased their target price on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, November 14th.

scPharmaceuticals Trading Down 3.3 %

Shares of SCPH opened at $3.18 on Wednesday. scPharmaceuticals has a 12-month low of $3.08 and a 12-month high of $6.20. The firm has a market capitalization of $159.13 million, a P/E ratio of -1.67 and a beta of 0.11. The firm has a 50-day moving average price of $3.39 and a 200 day moving average price of $3.96. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66.

Institutional Trading of scPharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Thrivent Financial for Lutherans increased its position in shares of scPharmaceuticals by 1.4% during the third quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock valued at $4,783,000 after acquiring an additional 14,866 shares during the last quarter. King Luther Capital Management Corp boosted its position in shares of scPharmaceuticals by 0.9% during the 3rd quarter. King Luther Capital Management Corp now owns 2,225,790 shares of the company’s stock worth $10,150,000 after purchasing an additional 20,650 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in scPharmaceuticals in the 3rd quarter valued at approximately $57,000. BNP Paribas Financial Markets raised its position in scPharmaceuticals by 116.9% in the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after purchasing an additional 3,101 shares during the period. Finally, Rubric Capital Management LP lifted its stake in scPharmaceuticals by 35.5% during the third quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after purchasing an additional 1,250,000 shares in the last quarter. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.